Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors
NCT01065623
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated due to safety reasons
Conditions
Neoplasms
Interventions
DRUG:
BAY79-4620
Sponsor
Bayer